Skip to content

Real-world Access to T cell-directed Therapies in Multiple Myeloma: Driving Away Health Disparities
Tweetorial #2
*Activity Post-Survey & Application for CME Credit*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.What are your credentials? (Required.)
2.What is your community of practice?
3.Relative to White patients, which of the following is more likely to be observed in African American patients diagnosed with Myeloma?
4.Compared with White patients, Black patients with myeloma are more likely to experience which of the following?
5.Which of the following racial/ethnic groups has the highest rate of clinical trial ineligibility in multiple myeloma?
6.How many of the 4 U.S. states where more than 30% of the population is composed of Black people had open clinical trials for CART T-cell therapy or bispecific antibodies for myeloma?
EVALUATION FORM
7.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
IDENTIFY disparities and potential strategies to inequities in the management of patients with multiple myeloma.
8.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
The educational resources provided to me at the educational activity are useful to my practice.
9.Overall, was this activity fair, balanced and free from commercial bias?
10.If no, please explain:
11.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
12.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
13.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
14.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
15.I certify that I have participated in the continuing education activity entitled, "Real-world Access to T cell-directed Therapies in Multiple Myeloma: Driving Away Health Disparities" and claim 0.25 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice